| Anti TNF | Delay of anti TNF introduction (days) | Duration of anti TNF if stop possible (months) | Duration of anti TNF (ongoing) (years) | Evolution | Duration of follow-up under anti TNF (months) |
|---|---|---|---|---|---|
| ADA | 3386 | Pso Ar | 51.6 | ||
| IFX | 193 | 3.5 | remission | 1.6 | |
| ETN | 70 | 4 | remission | 3.9 | |
| ETN | 59 | 5.4 | SpA | 78.4 | |
| ETN | 230 | 5.0 | SpA | 56.6 | |
| ETN | 1485 | 10 | lost FU | 10.4 | |
| ETN | 11 | 4.8 | remission | 35.3 | |
| ETN | 335 | 3.8 | SpA | 56.3 | |
| ETN | 116 | 3.7 | SpA | 33.7 | |
| ADA | 79 | 3.4 | SpA | 46 | |
| ETN | 464 | 2.5 | SpA | 39.3 | |
| IFX | 83 | 5 | remission | 5.5 | |
| IFX | 39 | 2 | remission | 2.6 | |
| ADA | 454 | SpA | 22.1 | ||
| ETN | 96 | 15 | 0.5 | SpA | 20.4 |